Business
Business Update - Correction
Business Update - Correction.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 1878J\n SkinBioTherapeutics PLC\n 19 August 2021\n \n \n \n \n 19 August 2021\n \n \n \n \n \n SkinBioTherapeutics plc\n \n \n (\"SkinBioTherapeutics\" or \"the Company\")\n \n \n \n \n \n Business Update - Correction\n \n \n \n \n \n This is restatement of the announcement published at 07:00 on 19 August 2021 (RNS number 1501J) to correct the manufacturing scale-up volume of SkinBiotix from the originally stated \"20,000 cubic metres\" to \"\n 20 cubic metres\". \n \n \n All other details remain unchanged. The full corrected announcement is set out below.\n \n \n \n \n \n SkinBioTherapeutics plc\n \n \n (\"SkinBioTherapeutics\" or \"the Company\")\n \n \n \n \n \n Business Update\n \n \n \n · \n AxisBiotix-Ps™ now regulatory compliant in the US, UK and EU;\n \n \n · \n Commercial launch of AxisBiotix-Ps™ remains on track for Q4 2021; \n \n \n · \n Further analysis of the AxisBiotix data set shows some encouraging potential for other skin conditions including eczema, acne and rosacea;\n \n \n · \n SkinBiotix manufacturing scale-up with Croda progressing to schedule;\n \n \n · \n Cash at 30 June 2021 £4.6m (31 December 2020 £5.5m)\n \n \n \n \n \n SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, has today provided a business update including an update on plans for commercialisation of \n AxisBiotix-Ps™ as committed to in the announcement of 26 May 2021\n . In summary, o\n perationally, the Company has made significant progress with its plans to launch AxisBiotix-Ps™ in Q4 2021 and scale-up SkinBiotix to commercial volumes. Financially, the Company ended the 12 months to 30 June 2021 with a solid cash balance of £4.6m (31 December 2020: £5.5m). \n \n \n \n \n \n \n AxisBiotix-Ps\n \n \n ™\n \n \n \n \n \n \n Study results\n \n \n In May 2021 the Company reported on the outcomes of the study for participants that self-identified as suffering from psoriasis. For the full report, please visit the AxisBiotix website www.axisbiotix.com. The results were very positive and provided definitive support for the commercial development of AxisBiotix-Ps™ which will be launched in Q4 2021 as a probiotic food supplement to help alleviate the symptoms of psoriasis.\n \n \n \n \n \n Even though the study was originally ...